We performed a population-based historical cohort study using the Surveillance, Epidemiology, and End Results (SEER) database to determine trends in the incidence of major salivary gland cancer and to evaluate the effect of sex, tumor size, histology, primary site, and extent of disease. Participants were men and women with major salivary gland cancer, diagnosed 1973-2009. The incidence of major salivary gland cancer increased from 10.4 per 1,000,000 in 1973 to 16 per 1,000,000 in 2009 (annual percent change [APC] 0.99; 95% confidence interval [CI] 0.78 to 1.20; p < 0.05). The incidence of parotid cancers increased (APC 1.13; 95% CI 0.88 to 1.39; p < 0.05) and paralleled the increase in major salivary gland cancer overall. There was an increase in the incidence of tumors measuring 0 to 2.0 cm (APC 1.99; 95% CI 0.61 to 3.38; p < 0.05), but no change in tumors measuring 2.1 to 4.0 cm (APC 1.02; 95% CI -0.46 to 2.52; p > 0.05) and tumors measuring >4 cm (APC -0.52; 95% CI -1.72 to 0.69; p > 0.05). There was an increase in the incidence of regional (APC 0.77; 95% CI 0.32 to 1.23; p < 0.05) and distant (APC 2.43; 95% CI 1.43 to 3.45; p < 0.05) disease, but not localized disease (APC 0.35; 95% CI 0 to 0.71; p > 0.05). We conclude that the incidence of major salivary gland cancer is increasing, especially small parotid tumors. The incidence of tumors with regional and distant metastasis is also increasing. These findings highlight the need for further research on the etiology of salivary gland cancer, which may reveal opportunities for further public health efforts aimed at prevention.
Introduction
As various risk factor and lifestyle modifications are introduced into medical practice, epidemiologic reports have noted a decrease in cancer incidence over the years. 1, 2 A recently issued National Cancer Institute report revealed a fluctuation over the years, with a noted significant decrease in cancer trends of all sites over the past decade. 1 A closer look at the key indicator cancers such as prostate, breast cancer, colorectal, and lung cancer all had decreased incidence rates over the previous decade.
Several studies have demonstrated decreasing incidence in some subsites of the head and neck while showing increasing incidence in others. A study by Davies et al revealed an increase in in thyroid cancer incidence from 1973 to 2002, which they attributed to increased detection of subclinical disease. 3 Another study on the epidemiology of head and neck cancer revealed decreasing incidence in lip, laryngeal, and oropharyngeal cancers. However, increasing incidence was noted for several subsites, including thyroid and salivary cancers. 4 Malignant salivary gland neoplasms comprise approximately 1 to 3% of all head and neck malignancies and approximately 0.3% of all malignant neoplasms. 5 Specifically, in the United States this proportion appears to be increasing. A study of head and neck cancer incidence trends revealed that salivary gland cancers comprised 6.3% of all head and neck cancers in 1974 to 1976, compared to 8.1% in 1998 to 1999. 6 Despite this increase, a clear etiology is not well elucidated. Although various risk factors have been evaluated, prior radiation exposure is thought to have the strongest predilection. 7 Several studies have examined the incidence of salivary gland cancer. 8, 9 However, these studies were limited to short periods and were therefore limited in their ability to demonstrate incidence trends.
Examining major salivary cancer incidence trends is important because an increase in incidence would indicate the need to redouble research efforts on un- derstanding the etiology of major salivary gland cancer, with the goal of instituting better preventive measures. The purpose of our study was to examine the incidence trends of major salivary gland cancer in the United States using a large population-based cancer database, and to evaluate the effect of sex, tumor size, histology, primary site, and extent of disease on its incidence trends.
Patients and methods
Data were obtained from the Surveillance, Epidemiology, and End Result (SEER) program of the National Cancer Institute, which includes data from 9 population-based registries: 5 states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and 4 standard metropolitan areas (Atlanta, Detroit, San Francisco-Oakland, and Seattle-Puget Sound). 10 Cases were defined as malignancies involving the following International Classification of Diseases for Oncology (ICD-O) site codes: C07.9 (parotid gland), C08.0 (submandibular gland), C08.1 (sublingual gland), C08.8 (overlapping lesion of major salivary glands, C08.9 (major salivary gland, NOS [not otherwise specified]).
Histology was grouped under the following ICD-O histology codes: mucoepidermoid carcinoma (8430/3), adenoid cystic carcinoma (8200/3), adenocarcinoma, NOS (8140/3), acinar cell carcinoma (8550/3), squamous cell carcinoma (8052/3, 8070/2, 8070/3, 8071/2, 8071/3, 8072/2, 8072/3, 8073/2, 8073/3, 8074/2, 8074/3, 8075/2, 8075/3, 8076/2, 8076/3, 8077/2, 8077/3, 8078/3, 8083/3, 8084/3), malignant mixed tumor (8022/3, 8940/3, 8941/3), other (all other histology codes not listed above).
SEER historic stage was coded as localized, regional, or distant. Tumor size was coded as the largest tumor dimension. This was grouped into 3 categories: 0 to 2.0 cm, 2.1 to 4.0 cm, and >4 cm.
Overall, sex-specific, historicstage-specific, histology-specific, and site-specific incidence trends were calculated from 1973 to 2009. Size-specific incidence trends for parotid malignancies were calculated from 1988 to 2003 because size data are only available for cases diagnosed in 1988 or later.
The SEER computer software (SEER*Stat 7.0.9) was used for statistical analysis. Incidence trend was evaluated by calculating the annual percent change (APC) with 95% confidence intervals (CIs). A p value <0.05 was considered statistically significant.
This study was exempt from Mount Sinai School of Medicine Institutional Review Board review because it was conducted using public data.
Results
The incidence of major salivary gland cancer increased from 10.4 per 1,000,000 in 1973 to 16 per 1,000,000 in 2009, a 54% increase. This increase was statistically significant (APC 0.99; 95% CI 0.78 to 1.20; p < 0.05). This increase was seen in both men and women (APC 0.97 and 0.96, respectively; p < 0.05).
There was an increase in the incidence of regional (APC 0.77; 95% CI 0.32 to 1.23; p < 0.05) and distant (APC 2.43; 95% CI 1.43 to 3.45; p < 0.05) disease. However, there was no change in the incidence of localized disease (APC 0.35; 95% CI 0 to 0.71; p > 0.05).
The incidence (per 1,000,000) increased from 2.29 to 3.08 for mucoepidermoid carcinoma (APC 0.47; 95% CI 0.02 to 0.92; p < 0.05), from 1.28 to 2.17 for acinar cell carcinoma (APC 1.73; 95% CI 1.05 to 2.42; p < 0.05), and from 1.19 to 2.32 for squamous cell carcinoma (APC 1.53; 95% CI 1.09 to 1.97; p < 0.05). There was no change in the incidence of adenocarcinoma, NOS (APC -0.39; 95% CI -1.20 to 0.43; p > 0.05). There was a decrease in the incidence of adenoid cystic carcinoma (APC -1.64; 95% CI -2.17 to -1.10; p < 0.05) and malignant mixed tumor (APC -0.92; 95% CI -1.76 to -0.07; p < 0.05).
As shown in figure 1 , the incidence of parotid cancers increased (APC 1.13; 95% CI 0.88 to 1.39; p < 0.05) and paralleled the increase in major salivary gland cancer overall, suggesting that the bulk of this incidence increase was due to parotid cancers. There was a smaller, but statistically significant increase in the incidence of Figure 2 shows the incidence trends for parotid cancer by tumor size. There was an increase in the incidence of tumors measuring 0 to 2.0 cm (APC 1.99; 95% CI 0.61 to 3.38; p < 0.05). There was no change in the incidence of tumors measuring 2.1 to 4.0 cm (APC 1.02; 95% CI -0.46 to 2.52; p > 0.05) and tumors measuring >4 cm (APC -0.52; 95% CI -1.72 to 0.69; p > 0.05).
Discussion
Our investigation demonstrated a significant increase in the incidence of major salivary gland cancer, noted both in men and women. The incidence of regional and distant disease increased; however, the incidence of localized tumors remained the same. There was an increase in the incidence of parotid and submandibular tumors. The parotid tumor incidence paralleled the overall major salivary gland tumor incidence curve, suggesting that the bulk of this incidence increase was due to parotid cancers.
Changes in histologic subtype also were noted. There was an increase in mucoepidermoid carcinoma, acinar cell carcinoma, and squamous cell carcinoma, no change in adenocarcinoma, and a significant decrease in the incidence of adenoid cystic carcinoma and malignant mixed tumor. When examining parotid tumor size, a significant increase in incidence was noted in smaller tumors measuring 0 to 2.0 cm, with no appreciable increase in larger tumors (>2.1 cm).
While it has been reported that the incidence of many head and neck cancers in the United States is decreasing, 4 our data demonstrate that the incidence of major salivary gland malignancy, especially parotid gland tumors, has steadily increased since 1973.
The preponderance of parotid malignancy is in line with other trends reported in the literature. A study by Carvalho et al using the SEER database found a disproportionate increase in the prevalence of parotid cancer compared with other head and neck cancers. 6 Another study by Sun et al noted no significant change in the incidence of salivary gland carcinoma over time. 9 It is interesting that the overall increase in the incidence of major salivary gland malignancy appears to be primarily driven by parotid malignancies. The reason for this is unknown, but it may be because most salivary gland malignancies occur in the parotid. [11] [12] [13] Our study showed an increase in the incidence of regional and distant disease, while the incidence of localized tumors remained the same. In contrast, Carvalho et al, when examining the period of 1974 to 1999, noted a decrease in patients diagnosed with local stage, while observing no significant change in those with regional or distant disease. 6 It is unclear why there is a disproportionate increase in the incidence of regional and distant disease, but improvement in clinical staging due to novel diagnostic and imaging techniques might have led to more accurate detection of regional and distant metastasis, thereby leading to clinical upstaging. 6 As noted by Davies et al, early detection due to improved and widespread use of diagnostic and imaging technique may also account for the increasing incidence of smaller tumors. 3 The increase in the incidence of salivary gland malignancy is concerning because the etiology of major salivary gland cancer is not clearly understood. Compared to other cancers of the head and neck, major salivary gland malignancy is not linked to the consumption of alcohol and tobacco products. The reason for the rise in incidence cannot be elucidated from our study. However, it is known that radiation exposure is a risk factor, raising the possibility that increased exposure to radiation from diagnostic testing may be a contributing factor. 7, [14] [15] [16] Other hypothesized links noted in the literature DEL SIGNORE, MEGWALU include breast cancer, ultraviolet B radiation, viral exposure, hormonal exposure, and a variety of chemical exposures. [17] [18] [19] Therefore, new exposures introduced into the environment over the years might have contributed to the increase in incidence. It is possible that the increased incidence may be simply due to increased diagnostic scrutiny. However, this is unlikely given that salivary gland malignancies are unlikely to remain asymptomatic for long. As with all population-based studies, the accuracy of our results is limited by the accuracy of information entered in the database. Fortunately, this is minimized by using standardized coding strategies across all the cancer registries that participate in the SEER program.
The strengths of our study lie in its large sample size and the diverse inclusion population. The catchment areas used in the SEER database were selected for their ability to maintain a high-quality cancer-reporting system and for demographic characteristics that are representative of the entire US population.
In conclusion, the incidence of major salivary gland cancer is increasing. This increase is primarily driven by parotid tumors. The incidence of smaller tumors, with regional and distant metastasis, is increasing, possibly due to earlier detection and improved clinical staging. However, the reason for this rising incidence in major salivary gland cancer is unknown.
Most studies on salivary gland cancer focus on diagnosis and management. Our study highlights the need for further research on the etiology and risk factors for major salivary gland cancer. However, given the relatively low incidence, prospective cohort studies may not be feasible. High-quality case-control studies are needed to explore potential risk factors for salivary gland cancer. Better understanding of the etiology may reveal opportunities for public health efforts to reduce the incidence.
